Half-life, clearance and AUC of [D10]PheT after oral dosing and smoking
Paired t test was performed to compare the effects of routes of administration. Results were not significant, p > 0.05.
| ID | t1/2 | CL7 | AUC(PheT) | |||
|---|---|---|---|---|---|---|
| Oral | Smoking | Oral | Smoking | Oral | Smoking | |
| h | l/h | nmol ยท h/l | ||||
| 1 | 7.2 | 10.9 | 7.8 | 13.2 | 1.07 | 1.43 |
| 2 | 17.7 | 8.1 | 3.1 | 7.3 | 0.13 | 0.11 |
| 3 | 12.6 | 11.4 | 5.8 | 6.4 | 0.97 | 1.06 |
| 4 | 11.0 | 6.7 | 4.9 | 6.4 | 0.37 | 0.38 |
| 5 | 3.9 | 4.8 | 5.5 | 4.8 | 0.24 | 0.48 |
| 6 | 6.3 | 7.5 | 4.3 | 7.3 | 1.10 | 1.49 |
| 7 | 12.6 | 8.1 | 4.5 | 13.0 | 0.97 | 0.13 |
| 8 | 5.5 | 5.9 | 5.4 | 4.6 | 0.46 | 0.51 |
| 9 | 6.4 | 9.8 | 3.2 | 1.3 | 1.04 | 0.81 |
| 10 | 6.9 | 7.5 | 5.1 | 7.1 | 0.55 | 0.48 |
| 11 | 4.9 | 4.5 | 7.5 | 3.1 | 0.85 | 0.70 |
| 12 | 4.4 | 6.4 | 3.2 | 3.6 | 0.43 | 0.48 |
| 13 | 7.9 | 9.9 | 6.0 | 7.0 | 0.58 | 0.76 |
| 14 | 7.4 | 7.1 | 4.0 | 4.5 | 1.70 | 1.11 |
| 15 | 8.8 | 6.0 | 4.6 | 4.0 | 0.94 | 0.53 |
| 16 | 5.1 | 5.2 | 4.4 | 4.5 | 0.93 | 0.87 |
| 17 | 9.3 | 7.5 | 1.9 | 1.9 | 1.98 | 1.27 |
| 18 | 6.1 | 11.0 | 2.2 | 2.2 | 0.80 | 0.65 |
| 19 | 5.4 | N.A. | 1.8 | N.A. | 0.90 | N.A. |
| 20 | 5.2 | 6.2 | 3.7 | 4.1 | 1.04 | 1.02 |
| 21 | 7.4 | 9.8 | 3.2 | 2.9 | 1.45 | 0.69 |
| 22 | 5.8 | 8.9 | 2.8 | 4.7 | 0.82 | 1.53 |
| 23 | 7.0 | 6.7 | 3.0 | 5.1 | 2.08 | 1.45 |
| 24 | 4.8 | 7.3 | 5.3 | 3.0 | 1.29 | 1.57 |
| 25 | 6.3 | 6.9 | 2.4 | 2.9 | 0.65 | 0.79 |
| Mean | 7.4 | 7.7 | 4.2 | 5.2 | 0.93 | 0.85 |
| S.D. | 3.2 | 2.0 | 1.6 | 3.0 | 0.49 | 0.44 |
N.A., not available because the plasma concentration of [D10]PheT of subject 19 after smoking was below the limit of quantitation.